Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of the Broadly Neutralizing Antibody BNT351 in Adults Living Without and With HIV

NCT07392372 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT07392372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of the Broadly Neutralizing Antibody BNT351 in Adults Living Without and With HIV
Lead sponsor
BioNTech SE
Phase
Phase 1
Overall status
Recruiting
Start date
February 9, 2026
Completion date
June 30, 2027
Enrollment
67 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hiv -1 infection